We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$240M
Cap. Flow
+$114M
Cap. Flow %
4.13%
Top 10 Hldgs %
48.06%
Holding
144
New
27
Increased
15
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$58.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$54.6M
3
JNJ icon
Johnson & Johnson
JNJ
+$45.1M
4
ALKS icon
Alkermes
ALKS
+$27.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$24.1M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$21.9M
3
PRGO icon
Perrigo
PRGO
+$21.6M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$19.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 84.12%
2 Real Estate 3.08%
3 Financials 1.53%
4 Technology 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
76
CALL
DELISTED
MEDIVATION, INC.
MDVN
$6.13M 0.22%
+107,400
New +$6.62M
MDVN
77
DELISTED
MEDIVATION, INC.
MDVN
$6.13M 0.22%
+107,400
New +$6.62M
THC icon
78
CALL
Tenet Healthcare
THC
$21.8B
$6.08M 0.22%
+105,000
New +$5.36M
HCA icon
79
CALL
HCA Healthcare
HCA
$85.7B
$6.01M 0.22%
+66,300
New +$5.31M
ENDP
80
CALL
DELISTED
Endo International plc
ENDP
$5.9M 0.21%
+74,100
New +$6.4M
IONS icon
81
CALL
Ionis Pharmaceuticals
IONS
$8.81B
$5.65M 0.2%
+98,200
New +$6.24M
IONS icon
82
Ionis Pharmaceuticals
IONS
$8.81B
$5.65M 0.2%
+98,200
New +$6.24M
AGN.PRA
83
DELISTED
Allergan plc
AGN.PRA
$5.21M 0.19%
+5,000
New +$5.23M
ACHN
84
DELISTED
Achillion Pharmaceuticals
ACHN
$4.85M 0.18%
547,300
– –
EPZM
85
DELISTED
Epizyme, Inc
EPZM
$4.8M 0.17%
200,000
– –
FOMX
86
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.24M 0.15%
+413,800
New +$4.57M
KYTH
87
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$4.2M 0.15%
55,717
– –
WMGI
88
DELISTED
Wright Medical Group Inc
WMGI
$4.1M 0.15%
156,100
– –
DCOY
89
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
AEGR
90
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.91M 0.14%
206,000
– –
AXDX
91
DELISTED
Accelerate Diagnostics
AXDX
$3.73M 0.14%
14,463
– –
MYGN icon
92
Myriad Genetics
MYGN
$507M
$2.54M 0.09%
74,800
– –
BDSI
93
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.99M 0.07%
250,000
– –
GNMK
94
DELISTED
GenMark Diagnostics, Inc
GNMK
$1.95M 0.07%
+215,149
New +$2.17M
DERM
95
DELISTED
Dermira, Inc.
DERM
$1.71M 0.06%
+97,197
New +$1.5M
CLLS
96
Cellectis
CLLS
$287M
$1.44M 0.05%
40,000
– –
TRIL
97
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.42M 0.05%
+65,000
New +$1.48M
BLCM
98
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.28M 0.05%
6,000
– –
ABAX
99
DELISTED
Abaxis Inc
ABAX
$1.16M 0.04%
+22,466
New +$1.26M
SAGE
100
DELISTED
Sage Therapeutics
SAGE
$1.09M 0.04%
15,000
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Tekla Capital Management held 144 positions worth $2.76B, up 9.5% from $2.52B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management deployed $114M of net new capital in Q2 2015, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Humana: 112,000 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was AbbVie, an estimated $72.5M trimmed.

  • Tekla Capital Management's largest Q2 2015 buy was Humana: 112,000 shares worth $21.4M.
  • Tekla Capital Management added most to Viatris in Q2 2015, an estimated $58.4M increase.
  • Tekla Capital Management's biggest Q2 2015 reduction was AbbVie, cutting an estimated $72.5M.
  • Tekla Capital Management fully exited Perrigo in Q2 2015, selling an estimated $21.6M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q2 2015.
  • Tekla Capital Management opened 27 new positions and closed 28 in Q2 2015.
  • Tekla Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.